Kunming Longjin Pharmaceutical Co., Ltd. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was CNY 121.15 million compared to CNY 698.35 million a year ago. Revenue was CNY 122.97 million compared to CNY 702.52 million a year ago.

Net loss was CNY 56.12 million compared to net income of CNY 3.09 million a year ago. Basic loss per share from continuing operations was CNY 0.1401 compared to basic earnings per share from continuing operations of CNY 0.0077 a year ago. Diluted loss per share from continuing operations was CNY 0.1401 compared to diluted earnings per share from continuing operations of CNY 0.0077 a year ago.